Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01581528|
Recruitment Status : Completed
First Posted : April 20, 2012
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors identify learn more about biomarkers related to cancer. It may also help doctors to find better ways to treat cancer.
PURPOSE: This research studies samples from patients with T-cell acute lymphoblastic leukemia (T-ALL).
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Other: cell culture procedure Other: flow cytometry Other: laboratory biomarker analysis Other: metabolic assessment|
- Determine the metabolic status and regulation of primary T-cell acute lymphoblastic leukemia (T-ALL) relative to control resting peripheral T cells.
- Establish the effects of metabolic inhibition on metabolic stress pathways and apoptosis.
- Determine how metabolic inhibition interacts with chemotherapy or targeted therapy drugs to kill T-ALL cells.
OUTLINE: T-ALL samples cultured alone or with gamma secretase inhibitors (GSI) or PI3K inhibitors are analyzed for metabolic characteristics including glucose transporter 1 (Glut1) expression, mitochondrial mass, phospho-flow for 5' adenosine monophosphate-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), and mammalian target of rapamycin (mTOR) by flow cytometry. T-ALL samples and normal CD4+ T cells (control) are also exposed to ± 2-deoxyglucose or ± the glutaminolysis inhibitor media and analyzed for metabolic stress responses over time in particular, AMPK activation, autophagy (immunofluorescence for LC3-II processing), and BCL2-associated X protein (Bak) and Bax activation to indicate apoptosis. These cells (T-ALL and control) are then cultured with cyclophosphamide, dexamethasone, or the B-cell CLL/lymphoma 2 (Bcl-2) inhibitor, ABT-737, to determine cell death over time.
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||Metabolic Pathways in T-Cell Acute Lymphoblastic Leukemia (T-ALL)|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||May 2016|
- Metabolic status of primary T-ALL
- Effects of metabolic inhibition on metabolic stress pathways and apoptosis
- Metabolic inhibition interaction with chemotherapy or targeted drugs
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01581528
|Principal Investigator:||Jeffrey C. Rathmell, PhD||Duke Cancer Institute|